(Q85000719)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

Nadine A van der Beek

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Juna M de Vries

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Marian A Kroos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Lale Ozkan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Pieter A van Doorn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Susan M Richards

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Crystal C C Sung

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jan-Dietert C Brugma

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Adrienne A M Zandbergen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Ans T van der Ploeg

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Arnold J J Reuser

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

14 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

338-345

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease).

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

The long-term international safety experience of imiglucerase therapy for Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

A randomized study of alglucosidase alfa in late-onset Pompe's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: A case study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Hand-held myometry: reference values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Clinical features of late-onset Pompe disease: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Muscular weakness assessment: use of normal isometric strength data. The National Isometric Muscle Strength (NIMS) Database Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Standardisation of spirometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Predicted normal values for maximal respiratory pressures in caucasian adults and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Glycogen Storage Disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

Elimination of antibodies to recombinant enzyme in Pompe's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.08.009

10.1016/J.YMGME.2010.08.009

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20826098%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference